Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00757939 | A Study to Assess Regional Cerebral Blood Flow as an Alzheimer's Disease Biomarker Compared to Positron Emission Tomography in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects (Study MK-0000-068)(COMPLETED) | PHASE1 | COMPLETED | 40 | — | — | Sep 1, 2008 | Oct 1, 2010 | Aug 11, 2015 | - | — |
Part I: regional cerebral blood flow, measured by dASL at Baseline and 1 week in AD participants and cognitively normal controls. Part II: regional cerebral blood flow, measured at 6 months and 12 months in AD participants and normal control participants.
| Arm | Type | Description |
|---|---|---|
| AD Participants | EXPERIMENTAL | Participants with a diagnosis of mild-to-moderate AD |
| Cognitively Normal Elderly Participants | EXPERIMENTAL | Elderly participants with no cognitive impairment |
| Name | Type | Description |
|---|---|---|
| MRI | OTHER | During the study all participants will have 4 total MRI scans: baseline, 1 week, 6 and 12 months. |
| FDG-PET | OTHER | 2 to 4 PET scans will be done over 12 months, 2 planned and 2 more if data from any of these are un-interpretable |
Inclusion Criteria: The prospective participant must meet, at least, all of the criteria below (among others determined by the study staff) to be eligible for study participation. The participant: * Has mild-to-moderate Alzheimer's Disease (AD), OR is considered cognitively normal; * Has been on ...